The Wockhardt Group, previously a prominent player in the pharmaceutical industry, is facing monumental difficulties. With mounting debts and a struggling business, the group's substantial assets are now being put up for grabs. This sudden shift in fortunes has sent shockwaves through the industry, spurring speculation within financial circles. It